drugset / Trial / NCT00920088

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NCT00920088

Phase 1 Completed 24 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effect of GSK2448761 on CYP450 metabolic probes and to evaluate the 2-way interaction between GSK2448761 and two ritonavir-boosted protease inhibitors that are commonly used in HIV-infected subjects.

Timeline

Start
2009-06
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg
Subject Dextromethorphan Unknown 30 mg
Subject FOSDEVIRINE Small molecule
Subject Flurbiprofen Small molecule 50 mg
Subject Lopinavir Other / unclassified 400 mg
Subject Midazolam Small molecule 3 mg
Subject Ritonavir Other / unclassified 100 mg